385 related articles for article (PubMed ID: 32957644)
1. Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy.
Hensen LCM; Hoeben RC; Bots STF
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957644
[TBL] [Abstract][Full Text] [Related]
2. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.
Uusi-Kerttula H; Davies J; Coughlan L; Hulin-Curtis S; Jones R; Hanna L; Chester JD; Parker AL
Oncotarget; 2016 May; 7(19):27926-37. PubMed ID: 27056886
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.
Takagi-Kimura M; Yamano T; Tagawa M; Kubo S
Cancer Gene Ther; 2014 Mar; 21(3):126-32. PubMed ID: 24577130
[TBL] [Abstract][Full Text] [Related]
4. The Fiber Knob Protein of Human Adenovirus Type 49 Mediates Highly Efficient and Promiscuous Infection of Cancer Cell Lines Using a Novel Cell Entry Mechanism.
Baker AT; Davies JA; Bates EA; Moses E; Mundy RM; Marlow G; Cole DK; Bliss CM; Rizkallah PJ; Parker AL
J Virol; 2021 Jan; 95(4):. PubMed ID: 33268514
[TBL] [Abstract][Full Text] [Related]
5. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
[TBL] [Abstract][Full Text] [Related]
6. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.
Ingemarsdotter CK; Tookman LA; Browne A; Pirlo K; Cutts R; Chelela C; Khurrum KF; Leung EY; Dowson S; Webber L; Khan I; Ennis D; Syed N; Crook TR; Brenton JD; Lockley M; McNeish IA
Mol Oncol; 2015 Apr; 9(4):791-805. PubMed ID: 25560085
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic adenoviruses: design, generation, and experimental procedures.
Davydova J; Yamamoto M
Curr Protoc Hum Genet; 2013 Jul; Chapter 12():Unit 12.14. PubMed ID: 23853080
[TBL] [Abstract][Full Text] [Related]
11. In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus.
Adamson RE; Frazier AA; Evans H; Chambers KF; Schenk E; Essand M; Birnie R; Mitry RR; Dhawan A; Maitland NJ
Hum Gene Ther; 2012 Feb; 23(2):218-30. PubMed ID: 21823897
[TBL] [Abstract][Full Text] [Related]
12. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA.
Kim J; Nam HY; Kim TI; Kim PH; Ryu J; Yun CO; Kim SW
Biomaterials; 2011 Aug; 32(22):5158-66. PubMed ID: 21531456
[TBL] [Abstract][Full Text] [Related]
13. Ad5
Uusi-Kerttula H; Davies JA; Thompson JM; Wongthida P; Evgin L; Shim KG; Bradshaw A; Baker AT; Rizkallah PJ; Jones R; Hanna L; Hudson E; Vile RG; Chester JD; Parker AL
Clin Cancer Res; 2018 Sep; 24(17):4215-4224. PubMed ID: 29798908
[No Abstract] [Full Text] [Related]
14. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
15. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
[TBL] [Abstract][Full Text] [Related]
16. Toward the understanding of DSG2 and CD46 interaction with HAdV-11 fiber, a super-complex analysis.
Effantin G; Hograindleur M-A; Fenel D; Fender P; Vassal-Stermann E
J Virol; 2023 Nov; 97(11):e0091023. PubMed ID: 37921471
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma.
Bots STF; Harryvan TJ; Groeneveldt C; Kinderman P; Kemp V; van Montfoort N; Hoeben RC
Mol Oncol; 2024 May; 18(5):1245-1258. PubMed ID: 38037840
[TBL] [Abstract][Full Text] [Related]
18. Relationship between Cell Receptors and Tumor Cell Sensitivity to Oncolytic Enteroviruses.
Lipatova AV; Le TH; Sosnovtseva AO; Babaeva FE; Kochetkov DV; Chumakov PM
Bull Exp Biol Med; 2018 Nov; 166(1):58-62. PubMed ID: 30450519
[TBL] [Abstract][Full Text] [Related]
19. A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition.
Bagheri N; Shiina M; Lauffenburger DA; Korn WM
PLoS Comput Biol; 2011 Feb; 7(2):e1001085. PubMed ID: 21379332
[TBL] [Abstract][Full Text] [Related]
20. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells.
Liu Y; Chen L; Gong Z; Shen L; Kao C; Hock JM; Sun L; Li X
Oncotarget; 2015 Feb; 6(5):3055-70. PubMed ID: 25605010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
